Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.

Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, González A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F

Open source

DOI: 10.1093/ehjcvp/pvab031
Published: 2022 Feb 16
Container: European heart journal. Cardiovascular pharmacotherapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ehjcvp/pvab031,
  title = {Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.},
  author = {Ferreira JP and Collier T and Clark AL and Mamas MA and Rocca HB and Heymans S and González A and Ahmed FZ and Petutschnigg J and Mujaj B and Cuthbert J and Rouet P and Pellicori P and Mariottoni B and Cosmi F and Edelmann F and Thijs L and Staessen JA and Hazebroek M and Verdonschot J and Rossignol P and Girerd N and Cleland JG and Zannad F},
  year = {2022},
  journal = {European heart journal. Cardiovascular pharmacotherapy},
  doi = {10.1093/ehjcvp/pvab031},
  url = {https://doi.org/10.1093/ehjcvp/pvab031}
}

RIS

TY  - JOUR
TI  - Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
AU  - Ferreira JP
AU  - Collier T
AU  - Clark AL
AU  - Mamas MA
AU  - Rocca HB
AU  - Heymans S
AU  - González A
AU  - Ahmed FZ
AU  - Petutschnigg J
AU  - Mujaj B
AU  - Cuthbert J
AU  - Rouet P
AU  - Pellicori P
AU  - Mariottoni B
AU  - Cosmi F
AU  - Edelmann F
AU  - Thijs L
AU  - Staessen JA
AU  - Hazebroek M
AU  - Verdonschot J
AU  - Rossignol P
AU  - Girerd N
AU  - Cleland JG
AU  - Zannad F
PY  - 2022
JO  - European heart journal. Cardiovascular pharmacotherapy
DO  - 10.1093/ehjcvp/pvab031
UR  - https://doi.org/10.1093/ehjcvp/pvab031
ER  -

APA

JP, F., T, C., AL, C., MA, M., HB, R., S, H., A, G., FZ, A., J, P., B, M., J, C., P, R., P, P., B, M., F, C., F, E., L, T., JA, S., M, H., J, V., P, R., N, G., JG, C., & F, Z. (2022). Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.. European heart journal. Cardiovascular pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvab031

Source records

pubmed · retrieved 2026-09-26T11:01:15.613Z
europe-pmc · retrieved 2026-09-26T11:01:15.641Z
hal · retrieved 2026-09-26T11:01:15.651Z